Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Chemist aims to flush away tumours

22.03.2007
A researcher from the University of Bradford has been awarded a grant to investigate a way of flushing out cancerous tumours in the body with no potentially harmful side-effects.

Dr Klaus Pors, a Medicinal Chemist based at the University’s Institute of Cancer Therapeutics, has been awarded £96,474 by Yorkshire Cancer Research to develop a medicine that is harmless to the body but will help to eradicate tumours by using the cancer cell to convert a drug from something inactive to a powerful cell-killing agent.

The research centres on a group of proteins found in all humans called Cytochromes P450 (CYPs), which are most commonly found in the liver. They form part of the body’s immune system and their job is to metabolise compounds in the liver and other filter organs, making these compounds more ‘polar’ and enabling harmful substances to be excreted out of the body via the urinary system.

Whilst there are 57 known types of CYPs, some are known to be more highly present in cancer cells compared to the surrounding normal tissue. Dr Pors aims to exploit them by essentially hijacking the CYPs in the tumour to produce an agent that is highly damaging to the cancer cell DNA whilst leaving normal healthy cells alone.

... more about:
»Pors »side-effects »tumour

Dr Pors will be using the grant to employ a post-doctoral researcher to help develop these novel tumour-selective agents. He said: “A major obstacle in the treatment of cancer is the lack of selective killing of cancer cells. Clinicians currently use chemotherapeutic agents which generally damage normal tissues and lead to severe side-effects.

“It is envisaged that an agent would be administered to patients that produces no side-effects commonly associated with current therapies, but when reaching the tumour will be converted to an ultra-potent agent that causes the demise of the tumour.

“I’m delighted that Yorkshire Cancer Research has funded our work here, using money raised in the region for research in the region but more importantly, if our work is successful, patients all over the world could benefit from such highly targeted anti-cancer drugs that in principle will cause no harmful side-effects.”

Dr Pors and a team of researchers have spent the last 15 months analysing samples taken from cancer patients in Bradford and Leeds in order to get to this stage. If the lab-based work is successful, he hopes to move to Phase 1 Clinical Trials within five years.

Emma Banks | alfa
Further information:
http://www.cancer.brad.ac.uk/

Further reports about: Pors side-effects tumour

More articles from Life Sciences:

nachricht Not of Divided Mind
19.01.2017 | Hertie-Institut für klinische Hirnforschung (HIH)

nachricht CRISPR meets single-cell sequencing in new screening method
19.01.2017 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Traffic jam in empty space

New success for Konstanz physicists in studying the quantum vacuum

An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...

Im Focus: How gut bacteria can make us ill

HZI researchers decipher infection mechanisms of Yersinia and immune responses of the host

Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Sustainable Water use in Agriculture in Eastern Europe and Central Asia

19.01.2017 | Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

 
Latest News

New Study Will Help Find the Best Locations for Thermal Power Stations in Iceland

19.01.2017 | Earth Sciences

Not of Divided Mind

19.01.2017 | Life Sciences

Molecule flash mob

19.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>